Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01682226 · ClinicalTrials.gov registry record · Phase 2
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
A Phase 2 study of Lymphoma and Leukemia, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT01682226: Completed Phase 2 study of Lymphoma and Leukemia, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01682226 is a Phase 2 study of Lymphoma and Leukemia that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 84 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01682226, a Phase 2 study of Lymphoma and Leukemia, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out whether the addition of blood stem cells from a close family member, when added to umbilical cord blood will make the transplant safer.
Primary Outcome
The primary endpoint is neutrophil recovery ie the speed \[median (range) days to recovery\] and success \[day 45 cumulative incidence percent\].
Conditions Studied
Interventions
- DEVICE CliniMACS Fractionation system (Arm A)
- DEVICE CliniMACS Fractionation system (Arm B)
- BIOLOGICAL Haploidentical donor CD34+ cells
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2012-09-05 |
| Est. Completion | 2021-01-08 |
| Phase | Phase 2 |
What the finished NCT01682226 record still lists
NCT01682226 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (83% lower).
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which CliniMACS Fractionation system (Arm A) is the first listed.
NCT01682226 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01682226 about?
NCT01682226 is a clinical study titled "Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies". The purpose of this study is to find out whether the addition of blood stem cells from a close family member, when added to umbilical cord blood will make the transplant safer.
What is the current status of trial NCT01682226?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2012-09-05. Estimated completion is 2021-01-08.
What conditions does trial NCT01682226 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Myelodysplastic Syndrome.
What interventions are being tested in trial NCT01682226?
The interventions under investigation include: CliniMACS Fractionation system (Arm A) (DEVICE), CliniMACS Fractionation system (Arm B) (DEVICE), Haploidentical donor CD34+ cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01682226?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01682226 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01682226's enrollment target sits among peer trials
84 99th of 299 higher than 200 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI